Kancera AB (publ) announced that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer. Kancera has previously announced the decision to proceed into clinical development of its Fractalkine axis blocker KAND567 in ovarian cancer. Women with ovarian cancer are often diagnosed at a late stage and as a consequence, the probability of long-term survival (over 5 years) is greatly reduced.

The current standard of care for advanced ovarian cancer is platinum-based chemotherapy. However, the treatment has limitations, as cancer cells develop resistance to chemotherapy over time, through the ability to repair the DNA damage that chemotherapy causes. Kancera's planned study is a combined phase Ib/IIa study of the study-drug KAND567 in combination with platinum therapy in ovarian cancer patients with relapsed disease.

The aim of the combination treatment is to restore sensitivity to platinum treatment and ultimately prolong survival. The study is planned to be conducted at academic hospitals in Sweden, Denmark and Norway. Kancera has now submitted the first regulatory application to the Swedish Medical Products Agency and applications in Denmark and Norway are planned to follow in first quarter 2023.